Hyperinsulinemia fails to augment ET-1 action in the skeletal muscle vascular bed in vivo in humans

American Journal of Physiology - Endocrinology and Metabolism

Volumn 295, Issue 6, 2008, Pages

  Lteif, Amale A ^a   Fulford, Angie D ^a   Considine, Robert V ^a   Gelfand, Inessa ^a   Baron, Alain D ^a,b   Mather, Kieren J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Endothelin 1; Insulin; Obesity

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; INSULIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE;

ADULT; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LEG BLOOD FLOW; MALE; MUSCLE BLOOD FLOW; OBESITY; PRIORITY JOURNAL; VASOCONSTRICTION; VASODILATATION;

ADULT; ANTIHYPERTENSIVE AGENTS; ENDOTHELIN-1; FEMALE; HUMANS; HYPERINSULINISM; INSULIN; MALE; MUSCLE, SKELETAL; NITRIC OXIDE; OBESITY; OMEGA-N-METHYLARGININE; PEPTIDES, CYCLIC; RECEPTORS, ENDOTHELIN; VASOCONSTRICTION;

EID: 57349157849     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.90549.2008     Document Type: Article

References (56)

1. Ahlborg G, Lundberg JM. Nitric oxide-endothelin-1 interaction in humans. J Appl Physiol 82: 1593-1600, 1997.
2. Ahlborg G, Shemyakin A, Bohm F, Gonon A, Pernow J. Dual endothelin receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary artery disease. Diabetes Care 30: 591-596, 2007.
3. Baron AD, Laakso M, Brechtel G, Edelman SV. Reduced capacity and affinity of skeletal muscle for insulin-mediated glucose uptake in noninsulin-dependent diabetic subjects. Effects of insulin therapy. J Clin Invest 87: 1186-1194, 1991.
4. Baron AD, Zhu JS, Marshall S, Irsula O, Brechtel G, Keech C. Insulin resistance after hypertension induced by the nitric oxide synthesis inhibitor L-NMMA in rats. Am J Physiol Endocrinol Metab 269: E709-E715, 1995.
5. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 106: 1783-1787, 2002.
6. Cardillo C, Campia U, Iantorno M, Panza JA. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 43: 36-40, 2004.
7. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Panza JA. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 35: 1237-1241, 2000.
8. Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell JM. Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clin Exp Pharmacol Physiol 25: 175-184, 1998.
9. Eringa EC, Stehouwer CD, Merlijn T, Westerhof N, Sipkema P. Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles. Cardiovasc Res 56: 464-471, 2002.
10. Eringa EC, Stehouwer CD, Roos MH, Westerhof N, Sipkema P. Selective resistance to vasoactive effects of insulin in muscle resistance arteries of obese Zucker (fa/fa) rats. Am J Physiol Endocrinol Metab 293: E1134-E1139, 2007.
11. Eringa EC, Stehouwer CD, van Nieuw Amerongen GP, Ouwehand L, Westerhof N, Sipkema P. Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium. Am J Physiol Heart Circ Physiol 287: H2043-H2048, 2004.
12. Ferri C, Bellini C, Desideri G, De Mattia G, Santucci A. Endogenous insulin modulates circulating endothelin-1 concentrations in humans. Diabetes Care 19: 504-506, 1996.
13. Ferri C, Carlomagno A, Coassin S, Baldoncini R, Cassone Faldetta MR, Laurenti O, Properzi G, Santucci A, De Mattia G. Circulating endothelin-1 levels increase during euglycemic hyperinsulinemic clamp in lean NIDDM men. Diabetes Care 18: 226-233, 1995.
14. Ferri C, Pittoni V, Piccoli A, Laurenti O, Cassone MR, Bellini C, Properzi G, Valesini G, De Mattia G, Santucci A. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab 80: 829-835, 1995.
15. Gottsater A, Rendell M, Anwaar I, Lindgarde F, Hulthen UL, Mattiasson I. Increasing neopterin and decreasing endothelin-1 in plasma during insulin infusion in women. Scand J Clin Lab Invest 59: 417-424, 1999.
16. Hocher B, Schwarz A, Slowinski T, Bachmann S, Pfeilschifter J, Neumayer HH, Bauer C. In-vivo interaction of nitric oxide and endothelin. J Hypertens 22: 111-119, 2004.
17. Honing ML, Morrison PJ, Banga JD, Stroes ES, Rabelink TJ. Nitric oxide availability in diabetes mellitus. Diabetes Metab Rev 14: 241-249, 1998.
18. Hu RM, Levin ER, Pedram A, Frank HJ. Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes 42: 351-358, 1993.
19. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 104: 447-457, 1999.
20. Kashyap SR, Roman LJ, Lamont J, Masters BS, Bajaj M, Suraamornkul S, Belfort R, Berria R, Kellogg DL Jr, Liu Y, De-Fronzo RA. Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. J Clin Endocrinol Metab 90: 1100-1105, 2005.
21. Katsumori K, Wasada T, Saeki A, Naruse M, Omori Y. Lack of acute insulin effect on plasma endothelin-1 levels in humans. Diabetes Res Clin Pract 32: 187-189, 1996.
22. Kolka CM, Rattigan S, Richards S, Clark MG. Metabolic and vascular actions of endothelin-1 are inhibited by insulin-mediated vasodilation in perfused rat hindlimb muscle. Br J Pharmacol 145: 992-1000, 2005.
23. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 85: 1844-1852, 1990.
24. Li G, Barrett EJ, Wang H, Chai W, Liu Z. Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells. Endocrinology 146: 4690-4696, 2005.
25. Lteif A, Vaishnava P, Baron AD, Mather KJ. Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes 56: 728-734, 2007.
26. Maric C, Aldred GP, Antoine AM, Eitle E, Dean RG, Williams DA, Harris PJ, Alcorn D. Actions of endothelin-1 on cultured rat renomedullary interstitial cells are modulated by nitric oxide. Clin Exp Pharmacol Physiol 26: 392-398, 1999.
27. Mather K, Anderson TJ, Verma S. Insulin action in the vasculature: physiology and pathophysiology. J Vasc Res 38: 415-422, 2001.
28. Mather K, Laakso M, Edelman S, Hook G, Baron A. Evidence for physiological coupling of insulin-mediated glucose metabolism and limb blood flow. Am J Physiol Endocrinol Metab 279: E1264-E1270, 2000.
29. Mather K, Mirzamohammadi B, Lteif A, Steinberg H, Baron A. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes mellitus. Diabetes 51: 3517-3523, 2002.
30. Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 53: 2060-2066, 2004.
31. Metsarinne K, Saijonmaa O, Yki-Jarvinen H, Fyhrquist F. Insulin increases the release of endothelin in endothelial cell cultures in vitro but not in vivo. Metabolism 43: 878-882, 1994.
32. Miller AW, Tulbert C, Puskar M, Busija DW. Enhanced endothelin activity prevents vasodilation to insulin in insulin resistance. Hypertension 40: 78-82, 2002.
33. Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Johansen M, Kucik DF, Quon MJ, Draznin B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 277: 1794-1799, 2002.
34. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 28: 463-491, 2007.
35. Nagai M, Kamide K, Rakugi H, Takiuchi S, Imai M, Kida I, Matsukawa N, Higaki J, Ogihara T. Role of endothelin-1 induced by insulin in the regulation of vascular cell growth. Am J Hypertens 16: 223-228, 2003.
36. Oliver FJ, de la Rubia G, Feener EP, Lee ME, Loeken MR, Shiba T, Quertermous T, King GL. Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J Biol Chem 266: 23251-23256, 1991.
37. Piatti P, Fragasso G, Monti LD, Setola E, Lucotti P, Fermo I, Paroni R, Galluccio E, Pozza G, Chierchia S, Margonato A. Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels. Circulation 107: 429-436, 2003.
38. Piatti PM, Monti LD, Conti M, Baruffaldi L, Galli L, Phan CV, Guazzini B, Pontiroli AE, Pozza G. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes 45: 316-321, 1996.
39. Polderman KH, Stehouwer CD, van Kamp GJ, Gooren LJ. Effects of insulin infusion on endothelium-derived vasoactive substances. Diabetologia 39: 1284-1292, 1996.
40. Potenza MA, Marasciulo FL, Chieppa DM, Brigiani GS, Formoso G, Quon MJ, Montagnani M. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol 289: H813-H822, 2005.
41. Potenza MA, Marasciulo FL, Tarquinio M, Quon MJ, Montagnani M. Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance. Diabetes 55: 3594-3603, 2006.
42. Rab A, Dallinger S, Polak K, Pleiner J, Polska E, Wolzt M, Schmetterer L. Specific endothelin ET(A) receptor antagonism does not modulate insulin-induced hemodynamic effects in the human kidney, eye, or forearm. J Pharmacol Exp Ther 309: 692-696, 2004.
43. Rizzoni D, Porteri E, Piccoli A, Castellano M, Pasini G, Guelfi D, Muiesan ML, Rosei EA. High-dose, not low-dose insulin increases the vasoconstrictor effect of norepinephrine in spontaneously hypertensive rats: effects of antihypertensive treatment. J Vasc Res 36: 393-403, 1999.
44. Ross RM, Kolka CM, Rattigan S, Clark MG. Acute blockade by endothelin-1 of haemodynamic insulin action in rats. Diabetologia 50: 443-451, 2007.
45. Santure M, Pitre M, Marette A, Deshaies Y, Lemieux C, Lariviere R, Nadeau A, Bachelard H. Induction of insulin resistance by high-sucrose feeding does not raise mean arterial blood pressure but impairs haemodynamic responses to insulin in rats. Br J Pharmacol 137: 185-196, 2002.
46. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 94: 2511-2515, 1994.
47. Schiffrin EL, Touyz RM. Vascular biology of endothelin. J Cardiovasc Pharmacol 32: S2-S13, 1998.
48. Seljeflot I, Moan A, Aspelin T, Tonnessen T, Kjeldsen SE, Arnesen H. Circulating levels of endothelin-1 during acute hyperinsulinemia in patients with essential hypertension treated with type 1 angiotensin receptor antagonist or placebo. Metabolism 47: 292-296, 1998.
49. Setola E, Losa M, Lanzi R, Lucotti P, Monti LD, Castrignano T, Galluccio E, Giovanelli M, Piatti P. Increased insulin-stimulated endothelin-1 release is a distinct vascular phenotype distinguishing Cushing's disease from metabolic syndrome. Clin Endocrinol (Oxf) 66: 586-592, 2007.
50. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 94: 1172-1179, 1994.
51. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Kruszelnicka-Kwiatkowska O, Kokot F, Dubiel JS, Froelich JC. Effects of acute euglycemic hyperinsulinemia on urinary nitrite/nitrate excretion and plasma endothelin-1 levels in men with essential hypertension and normotensive controls. Metabolism 48: 887-891, 1999.
52. Verma S, Yao L, Stewart DJ, Dumont AS, Anderson TJ, McNeill JH. Endothelin antagonism uncovers insulin-mediated vasorelaxation in vitro and in vivo. Hypertension 37: 328-333, 2001.
53. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhausl W, Binder BR. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267: 16066-16068, 1992.
54. Wolpert HA, Steen SN, Istfan NW, Simonson DC. Insulin modulates circulating endothelin-1 levels in humans. Metabolism 42: 1027-1030, 1993.
55. Zaporowska-Stachowiak I, Gluszek J, Chodera A. Comparison of the serum insulin and endothelin level in patients with essential and renovascular hypertension. J Hum Hypertens 11: 795-800, 1997.
56. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101: 1539-1545, 2000.